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Abstract
Background: Continuous electronic fetal heart rate monitoring in labour is widely used but its potential for
improving fetal and neonatal outcomes has not been realised. The most likely reason is the difficulty of interpreting
the fetal heart rate trace correctly during labour. Computerised interpretation of the fetal heart rate and intelligent
decision-support has the potential to deliver this improvement in care.
This trial will test whether the addition of decision support software to aid the interpretation of the cardiotocogram
(CTG) during labour will reduce the number of ‘poor neonatal outcomes’ in those women judged to require
continuous electronic fetal heart rate monitoring.
Methods and design: An individually randomised controlled trial of 46,000 women who are judged to require
continuous electronic fetal monitoring in labour.
Eligibility criteria: Women admitted to a participating labour ward who are judged to require continuous electronic
fetal monitoring, have a singleton or twin pregnancy, are ≥ 35 weeks’ gestation, have no known gross fetal
abnormality and are ≥ 16 years of age.
Exclusion criteria: Triplets or higher order pregnancy, elective caesarean section prior to the onset of labour, planned
admission to NICU.
Trial interventions: Computerised interpretation of the CTG with decision-support.
Primary outcomes: Short term: A composite of ‘poor neonatal outcome’ including stillbirth after trial entry, early
neonatal death except deaths due to congenital anomalies, significant morbidity: neonatal encephalopathy,
admissions to the neonatal unit with 48 h for > 48 h with evidence of feeding difficulties, respiratory illness or
encephalopathy where there is evidence of compromise at birth. Long term: Developmental assessment at the age
of 2 years in a subset of 7000 surviving babies.
Data Collection: For all participating women and babies, labour variables and outcomes will be stored automatically
and contemporaneously onto the Guardian® system.
Discussion: The results of this trial will have importance for pregnant women and for health professionals who
provide care for them.
Trial registration: Current Controlled Trials ISRCTN98680152 assigned 30.09.2008
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Background
Continuous electronic fetal heart rate monitoring (EFM) in
labour is widely used throughout the developed world.
However, its potential for improving fetal and neonatal
outcomes has not been realised. The reasons for this are
complex, but the most likely reason is the difficulty of inter-
preting the fetal heart rate trace correctly during labour,
when the birth attendant has many competing tasks. If
intrapartum monitoring is ever going to improve fetal and
neonatal outcomes then the interpretation of the fetal heart
rate has to be substantially improved. This improvement
then has to be sustained and be independent of any health
professional’s individual ability. Computerised interpretation
of the fetal heart rate and intelligent decision-support has
the potential to deliver this improvement in care. The aim
of EFM is to detect abnormalities of the fetal heart rate pat-
tern during labour that are associated with asphyxia so that
action can be taken to expedite delivery and prevent still-
birth and the development of encephalopathy. Therefore
the potential benefits of EFM are immense. Prevention of
even a modest proportion of perinatal asphyxia will improve
the health and well-being of thousands of children and their
families throughout the world each year. In addition the
NHS Litigation Authority bill for obstetrics was £269 m in
2001/2 and is rising. This could be substantially reduced.
Furthermore, if this technology can work in the complex
process of labour it also has the potential to improve patient
safety in a wide range of health-care settings.
The problem of perinatal asphyxia
Perinatal asphyxia, if severe, can result in intrapartum still-
birth. If less severe it results in the development of an en-
cephalopathic state in the newborn. This is characterised by
a decreased level of consciousness, altered reflexes and ab-
normal tone and ultimately permanent damage to the
brain. Moderate or severe neonatal encephalopathy occurs
in approximately 2/1000 births [1]. With more severe as-
phyxial encephalopathy there is an increasing risk of death
or neurodevelopmental abnormalities: up to 30 % of af-
fected neonates will develop seizures and approximately
25 % of infants who have moderate asphyxial encephalop-
athy will develop cerebral palsy. Almost all infants with se-
vere encephalopathy die or survive with multiple handicaps
[2]. Perinatal asphyxia may account for up to 30 % of cases
of cerebral palsy [3] and it is a very significant health-care
and financial burden on the NHS. A reduction in the num-
ber of babies born with perinatal asphyxia would reduce
the associated mortality and, amongst survivors, the burden
of ill health and incapacity. It could also result in substantial
savings in litigation costs in the UK.
Efficacy of continuous electronic fetal monitoring (EFM)
Continuous EFM was invented in the 1960s [4, 5]. The
recorder displays the fetal heart rate and maternal uter-
ine activity and displays this on a continuous line graph,
called the cardiotocograph (CTG) tracing. EFM was
widely introduced in the 1970s [6]. It became controver-
sial in the 1980s when it was shown that it was poorly
predictive of Apgar scores and fetal acid–base status at
delivery [7]. The largest randomised controlled trial (the
Dublin trial) showed no reduction in perinatal mortality
or in cerebral palsy using EFM [8]. However, systematic
reviews and meta-analyses of all trials indicated some
benefits of continuous EFM: for example, a 58 % reduc-
tion in odds of deaths attributable to intrapartum hyp-
oxia (95 % confidence interval, 2 to 83 %) [9],
(see Table 1), and a 50 % reduction in risk of neonatal
seizures (95 % confidence interval, 20 to 69 %) [10].
EFM is widely used on many women during labour in
the UK. National Institute for Health and Care Excel-
lence (NICE) guidelines for fetal monitoring in the NHS
detail explicit criteria for which women should have
Table 1 The effect of continuous EFM versus intermittent auscultation on the incidence of deaths attributable to intrapartum hypoxia
No. of patients
in the EFM group
No. of patients
in the IA group
No. of perinatal deaths Perinatal deaths due to fetal hypoxia
Study EFM IA EFM IA
Haverkamp et al (1976) [45] 242 241 2 (FD 0, ND 2) 1 (FD 0, ND 1) 0 0
Renou et al (1976) [46] 175 175 1 (FD 0, ND1) 1 (FD 1, ND 0) 0 1 (FD)
Kelso et al (1978) [47] 253 251 0 1 (FD 0, ND 1) 0 1 (ND)
Haverkamp et al (1979) [48] 230 229 231 3 (FD 0, ND 3) 0 0 0
Wood et al (1981) [49] 445 482 1 (FD 0, ND 1) 0 0 0
MacDonald et al (1985) [8] 6474 6490 14 (FD 3, ND 11) 14 (FD 2, ND 12) 7 (FD 3, ND 4) 7 (FD 2, ND 5)
Neldam at al (1986) [50] 482 487 0 1 (FD 1, ND 0) 0 1 (FD)
Luthy et al (1987) [51] 122 124 17 (FD 1, ND 16) 18 (FD 1, ND 17) 0 1 (FD)
Vintzileos et al (1993) [52] 746 682 2 (FD 0, ND 2) 9 (FD 2,ND 7) 0 6 (FD 2, ND 4)
Total 9398 9163 40 (4.2/1000) 45 (4.9/1000) 7 (0.7/1000)a 17 (1.8/1000)a
EFM electronic fetal monitoring, IA intermittent auscultation, FD fetal (intrapartum) death, ND neonatal death
aStatistically significant difference; Mantel-Haenszel odds ratio 0.42 (95 % confidence interval 0.17 to 0.98)
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continuous EFM during labour; these equate to approxi-
mately 60 % of all women in labour [11].
Human error and systems failure
In the late 1980s it became apparent that a human elem-
ent might be a factor in EFM failing to deliver an
improved outcome. In one case–control study, the intra-
partum management of 38 babies severely asphyxiated at
birth was compared with that of 120 controls [12]. In the
control group, 29 % of babies had an abnormal CTG, but
in only 9 % was the abnormality severe. In contrast, 87 %
of the babies asphyxiated at birth had an abnormal CTG
and in 61 % of cases the abnormality was severe. The most
striking finding, however, was the length of time required
for the staff to recognise the CTG abnormality. With
moderate abnormalities, the mean time to recognition
was 91 min (SD 61); paradoxically, with severe abnormal-
ities it was 128 min (SD 100). The authors could give no
plausible reason for the standard of CTG interpretation
being so poor. However, it was clear from this study that if
the quality of interpretation of the intrapartum CTG had
been higher, the benefits from EFM would almost cer-
tainly have been significantly and substantially enhanced.
In 1990, Ennis and Vincent published the results of
their study of 64 cases of poor perinatal outcome from
the archives of the Medical Protection Society [13]. In
11 cases continuous EFM was not performed, although
indicated; in six cases the technical quality of the tracing
was inadequate; in 14 cases there was a significant ab-
normality in the CTG, but this was either not noticed or
no action was taken upon it; in only 14 cases was appro-
priate monitoring performed and action taken; and the
CTG was missing in 19 cases. In only 16 cases was a
consultant involved to aid in the interpretation of the
CTG. In a further study from Oxford published in 1994,
intrapartum care was assessed in 141 cases of cerebral
palsy and in 62 perinatal deaths with a likely intrapartum
cause [14]. The authors found that abnormal fetal heart-
rate patterns were: 2.3 times as common in babies who
went on to develop cerebral palsy, compared with con-
trols; and 6.7 times as common in perinatal deaths. In
addition, the authors found that clinicians’ failure to re-
spond to these clear signs of abnormality occurred in
26 % of cerebral palsy cases and 50 % of perinatal deaths,
compared with 7 % of controls. On the basis of these fig-
ures it can be estimated that approximately one case of
cerebral palsy and one perinatal death can possibly be
prevented in every 4500 deliveries. If one assumes
700,000 births per annum in the United Kingdom, 174
cases of cerebral palsy and 158 perinatal deaths could be
prevented each year. More recently, Stewart et al have
reported that perinatal mortality in the United Kingdom
is twice as high at night as during the day, and twice as
high in July and August as in the rest of the year [15].
They suggest that excess deaths may be due to over-
reliance on inexperienced staff at night and a shortage of
staff during the peak summer holiday months; they also
suggest that the excess might be related to physical and
mental fatigue of the caregivers. In 1999 the Confidential
Enquiry into Stillbirths and Deaths in Infancy (CESDI)
studied the proportion of 567 cases where there was evi-
dence of suboptimal care in labour. CESDI then looked
at whether improved care could possibly or probably
have prevented the adverse outcome [16]. Suboptimal
care was identified in 71 % of cases; a better outcome
could possibly (in 28 % of cases) or probably (in 22 % of
cases) have been anticipated, if care had been adequate.
The report commented that “fetal surveillance problems
were the most common cause [of problems in labour],
with CTG interpretation the most frequent criticism.”
Does improving training solve the problem?
In a report of a study of the efficacy of intrapartum interven-
tion, Young et al found that when babies with low Apgar
scores were studied, in 74 % there was evidence of substand-
ard care in labour [17]. Following the introduction of regular
audit of low Apgar scores, with intensive feedback to clinical
staff, this proportion fell to 23 %, but increased to 32 % over
the following year. However, following the introduction of
compulsory training in CTG interpretation for all staff, the
proportion of low Apgar score cases associated with sub-
standard care fell back once again to only 9 %. It is clear
from this study that improved interpretation of CTGs dur-
ing labour can bring about a striking increase in the quality
of care, with measurable impacts on neonatal condition.
However, intensive education is not sustainable in most clin-
ical settings. With recent changes in the training of junior
medical and midwifery staff, it is clear that other systems
have to be developed which are less reliant on individual
motivation and training. These systems need to work equally
well, regardless of the time of day, day of the week, month
of the year, and the level of staffing on the labour ward.
Litigation and the costs to families and society
Maternity services are associated with far higher litigation
costs than other services (http://news.bbc.co.uk/1/hi/
england/beds/bucks/herts/6310805.stm). This is reflected
in the various arrangements for the development of risk
management standards across the UK (Clinical Negligence
Scheme for Trusts in England, Welsh Risk Pool, Clinical
Negligence and Other Risks Indemnity Schemes and NHS
Quality Improvement Scotland in Scotland) [18].
Payments made (including amounts set aside for unre-
solved claims) by the National Health Service Litigation
Authority for obstetric related incidents over the period
1995 to 2005 totalled £1.5 billion.
In response to a parliamentary question on 29 Jan
2007, it was stated that the total compensation payout in
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2006 was £593 million, with £68 million resulting from
just ten cases, all of which were in relation to pregnancy
and childbirth. The BBC also reported a settlement of £6
million for a child with cerebral palsy after doctors
“mis-managed her delivery” (http://news.bbc.co.uk/1/hi/
england/beds/bucks/herts/6310805.stm). Even successful
defence can cost up to £0.5million. Not surprisingly, the
Chief Medical Officer set a target19 of a 25 % reduction in
obstetric mishaps by the year 2005. However in his 2006 re-
port there was still a chapter devoted to intrapartum related
deaths [19]. The BMJ in 2000 highlighted the importance of
“system errors” in medical disasters [20]; analogies were
drawn with errors in aviation. It has been suggested that
some techniques used in this industry could be applied ef-
fectively to medical care, such as safety drills, revalidation,
‘near miss’ reporting and a ‘no blame’ culture. The role of
expert systems and ‘intelligent alarms’ was highlighted.
The potential solution: development of the intelligent
decision-support software
A group in Plymouth, working on the problems of re-
solving human error in the management of labour, have
developed intelligent computer systems as decision aids
to support clinicians. The group were funded by the
MRC (G9721800) for development and clinical valid-
ation of a decision-support tool for the management of
labour using the CTG. This decision support software
interprets the CTG in the context of an individual
woman’s labour and offers advice on the management of
labour. It comprises feature extraction of all relevant
data from the CTG and clinical history which have been
found to influence clinicians’ decision making, and then
an analysis of these within a rule-based expert system.
The specific piece of decision-support software to be
evaluated in INFANT has been designed by K2 Medical
Systems (a spin-off company from the University of
Plymouth) to run on the K2 data collection system
(Guardian®). The data collection system (Guardian®) is a
system for managing information from labour monitor-
ing. It displays the CTG on a computer screen alongside
other clinical data which are collected as part of routine
clinical care. As such, it replaces conventional paper
labour notes, the CTG machine and other recording sys-
tems for documenting care during labour. The data col-
lection system (Guardian®) does not interpret any of the
data being collected, it merely acts as an interface to col-
lect and display data. If used to its full potential it results
in the labour room being a notes-free area.
The data collection system (Guardian)
The Guardian system consists of a medical-grade PC plat-
form, which meets the MHRA standards for a class IIa de-
vice. The design has been informed by user-preference
studies and ethnographic and audio-visual observations of
clinical care and decision making [21, 22]. It has a touch-
screen user-interface www.K2ms.com and is connected to
a conventional CTG recorder at the woman’s bedside.
The PC uses the Windows operating system and runs
the decision-support software developed by the Plymouth
Group. The clinician enters clinical information (antenatal
risk factors, vaginal examination data, fetal blood sample
results, etc.) via the touch-screen. This information is dis-
played as a partogram. The system requires little or no
training to use and has been used for routine clinical care
by a number of hospitals throughout the UK [23]. If a
CTG is performed by ultrasound or ECG clip, the PC sys-
tem automatically collects this from the RS 232 digital
data-port of any CTG recorder. The system displays the
CTG data on the screen (Fig. 1).
The decision-support software
The decision-support software is a specific piece of soft-
ware which has been developed to run on the Guardian®
system. It extracts the important features of baseline heart
rate, heart-rate variability, accelerations, type and timing
of decelerations, the quality of the signal and the contrac-
tion pattern from the CTG. The decision-support software
then analyses these data along with the quality of the sig-
nals. The system’s assessment of the CTG is presented as
a series of colour-coded alerts depending on the severity
of the abnormality detected. The system can therefore be
viewed as an intelligent prompt, but by recording the
chronology of events it also offers the opportunity to later
audit the actual clinical decision-making process in a simi-
lar way to an airliner’s black box.
Studies using the intelligent support software
Three studies conducted by the Plymouth group [24–26]
have demonstrated that the software, when used ‘off-
line’, performed as well as expert obstetricians in inter-
preting the CTG and managing labour subsequently,
and that the system performed better than routine clin-
ical practice. The system identified more cases that went
on to have a poor outcome and anticipated clinical
decision-making. In one of these studies involving
labours that had resulted in a stillbirth, the system
“intervened” more than six hours earlier than actual
clinical practice, and more than two hours before the ex-
perts. If this translated into clinical practice, it would be
reasonable to expect that a number of such deaths might
have been prevented if the software had been in use at
the time. In all other poor-outcome groups the system
intervened much earlier than had happened in routine
clinical practice and at a similar time as the experts. The
system failed to predict one perinatal death, whereas the
experts in the ‘off line’ study and those functioning in
routine clinical practice failed to predict several deaths.
These extensive ‘off-line’ validation studies have shown
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that the system matched the performance of an expert
obstetrician in interpreting the CTG, and performed
considerably better than routine clinical practice. Fur-
ther, the system is not over-interventional. From these
data it seems reasonable to hypothesise that the clinical
use of this computer-based decision-support software
will decrease the incidence of perinatal mortality and
morbidity.
Current practice
EFM is widely used for the majority of women dur-
ing labour and birth in the UK. NICE guidelines for
fetal monitoring detail explicit criteria indicating
which women should be offered continuous EFM
during labour; approximately 60 % of all women in
labour meet these criteria [11]. This study will not
influence the number of women who receive con-
tinuous EFM.
Research objectives
The objectives of the study are:
1. to determine whether intelligent decision-support
can improve interpretation of the intrapartum
cardiotocograph (CTG) and therefore improve the
management of labour for women who are judged to
require continuous electronic heart rate monitoring.
Specifically, will the system, compared with current
clinical practice:
i. identify more clinically significant heart rate
abnormalities?
ii. result in more prompt and timely action on
clinically significant heart rate abnormalities?
iii. result in fewer “poor neonatal outcomes”?
iv. change the incidence of operative interventions?
2. to assess whether use of intelligent decision-support
improves the quality of routine care received by
women undergoing continuous electronic fetal
monitoring during labour. This information will be
important for evaluating whether the decision-
support software decreases the risk of suboptimal
care in labour; it will also be useful to explore the
effect that such an intervention may have on
litigation for obstetrics.
3. to determine whether the use of the decision-
support software is cost-effective in terms of the
incremental cost per poor perinatal outcome
prevented.
4. to determine whether use of the decision-support
software has any effect on the longer term
neurodevelopment of children born to women
participating in the INFANT study.
Methods/Design
Research methods
An individually randomised controlled trial of 46,000
women who are judged to require continuous electronic
fetal monitoring in labour.
Fig. 1 The data collection system (Guardian) displays the CTG data on the screen
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Follow-up at age 2 years of a sample of 7000 surviving
children born to women participating in the INFANT study.
Trial eligibility and randomization
Women admitted to a participating labour ward who
fulfil all of the following criteria will be eligible to be
randomised if:
 they are judged to require continuous electronic
fetal monitoring (EFM) by the local clinical team
based on their existing guidelines, and the woman
consents to have EFM, and EFM is possible
Note: continuous EFM is defined as the active
decision of the health care professional and the
woman to initiate continuous EFM for the purpose of
fetal monitoring, usually because of a perceived risk
factor(s) which increases the likelihood of fetal
compromise occurring in labour. The Guardian
system will prompt the health care professional to
consider women eligible for the INFANT trial if the
CTG is used.
The decision to initiate continuous EFM can occur at
any time during labour. Some women with known
factors which place them at higher risk of fetal
compromise during labour will already know that
continuous fetal monitoring throughout labour is
planned. Others will start off labour with
intermittent monitoring and then be judged to
require continuous fetal monitoring at some point
during the labour. There is no point during labour at
which women are not eligible to participate (this
includes during the second stage).
 they have a singleton or twin pregnancy
 they are ≥ 35 weeks’ gestation (≥245 days)
 there is no known gross fetal abnormality, including
any known fetal heart arrhythmia such as heart
block
 they are 16 years of age or older
 they are able to give consent to participate in the
trial as judged by the attending clinicians.
Randomisation
The Guardian® system will prompt the health profes-
sional providing care to consider whether the woman is
eligible for the INFANT trial, when EFM has been used
for more than 5 min. Intermittent use of EFM for pe-
riods of up to 5 min duration may be used for intermit-
tent monitoring, but when used for longer periods of
time this will often indicate that a decision has been
made to initiate continuous EFM, in which case the
women may be eligible to participate in the trial. If the
health care professional indicates that the women is not
yet eligible because an active decision has not been made
to initiate continuous EFM, then the Guardian® system
will prompt the health care professional again, if the
CTG continues to be recorded for longer than 5 min in
this or any subsequent episode of monitoring.
When the health care professional indicates that a
woman is eligible to participate, the Guardian® system will
clarify that the necessary eligibility criteria for trial entry
have been met, i.e. that the health professional gives the
required answers to a number of questions posed by the
Guardian® system and then the Guardian® system will ran-
domly allocate the women in the ratio 1:1 to either “CTG
with no decision-support” or “CTG with decision-
support”. The allocations will be computer generated in
Stata software (release 10) using stratified block random-
isation employing variable block sizes to balance between
the two trial arms by whether the pregnancy is a singleton
or twins, and within each participating centre. The proce-
dures for randomisation will be fully documented,
reviewed and signed off prior to the start of the trial and
monitored by the co-ordinating centre during the trial.
As all de-identified information collected by the
Guardian® system within the participating centre can be
accessed centrally, the trial co-ordinating centre and the
participating centres will be able to monitor the per-
formance of centres in terms of the number of women
the Guardian system considers eligible who are recruited
to the trial to ensure that the necessary systems within
the centre are optimised to maximise recruitment.
Exclusion criteria
 triplets or higher order pregnancy
 criteria for EFM not met, including elective
caesarean section prior to the onset of labour
Planned interventions
The intervention is the decision-support software in this
trial. In order to accurately reflect any potential impact
of the decision-support software in contemporary NHS
practice, such as changes in midwifery presence during
labour consequent upon knowledge of the allocation, it
is desirable that clinicians are not masked to allocation.
Clinical management
The Guardian system will usually be used by all women
in labour in the participating centres. It is only the
decision-support software, which runs on this system,
that is being tested in this trial.
The clinical management of women participating in
this trial will remain unaltered by their participation,
apart from the relatively uncommon circumstances
when abnormalities of the CTG prompt the system in
the ‘decision-support’ arm of the trial to issue a series of
alerts or alarms, which will increase in urgency with the
severity of the abnormality (See Fig. 2).
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Information about the trial will be provided to all
women during the antenatal period, after their booking
appointment. This process will be individualised for each
participating centre depending on their routine prac-
tices. For example, in some centres, women will be pro-
vided with information about the trial at their routine
ultrasound scan appointment (18–22 weeks). All women
will have the opportunity to ask questions.
When a woman presents in early labour to the labour
ward in a participating centre, she will be given a copy of
the Participant Information Leaflet and a verbal explan-
ation of the INFANT trial. She will then be asked whether
she would like to participate in the study and if she agrees
she would be asked to sign an INFANT trial consent form.
If then at any point continuous electronic fetal monitoring
(EFM) is commenced, then the midwife responsible for
her care will check her eligibility to participate in the trial
and check that the woman is still happy to take part and
document this, then the woman will be randomised by the
Guardian® system to either decision-support (intervention
arm) or no decision-support (control arm).
All women admitted in labour to the participating cen-
tres will usually have their labour information recorded
in the Guardian® system, according to the current prac-
tice in each centre. This does not change the way health
professionals manage labour, it merely changes the way
they manage the information generated by the process
of monitoring labour and how they record this
information. It will be clearly stated that women are free
to withdraw from the study at any time for any reason
without prejudice to future care, and with no obligation
to give the reason for withdrawal.
Written informed consent will be obtained by means
of a dated signature from the woman and the signature
of the person who obtained informed consent; this
would be the Principal Investigator (or a qualified health
care professional with delegated authority). A copy of
the signed informed consent document will be given to
the women. A further copy will be retained in the woman’s
medical notes, a copy will be retained by the Principal
Investigator and a final copy will be sent to the Trial Coord-
inating Centre.
A senior investigator will be available at all times to
discuss concerns raised by women or clinicians during
the course of the trial.
Outcome measures
The primary outcomes of this trial will be:
Short term
A composite of ‘poor neonatal outcome’ to include (a)
all deaths (intrapartum stillbirths plus neonatal deaths
i.e. deaths up to 28 days after birth) except deaths due
to congenital anomalies, (b) significant morbidity: neo-
natal encephalopathy (moderate and severe); (c) admis-
sions to the neonatal unit within 48 h of birth for ≥ 48 h
Fig. 2 Clinical Management flow diagram
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with evidence of feeding difficulties, respiratory illness
or encephalopathy where there is evidence of comprom-
ise at birth. (We recognise that the signs of mild enceph-
alopathy can be subtle and hence a number of such
babies are likely to have a range of non-specific signs
such as respiratory difficulty and poor feeding rather
than features more specifically associated with encephal-
opathy [27]. Hence including admission to the neonatal
unit within 48 h of birth for equal to or greater than
48 h where there is evidence of compromise at birth.
Since this is a mature group of babies, any difference in
the incidence of these admissions is likely to result from
differences in perinatal asphyxia).
Note: the benefit of using a composite outcome is the
increased incidence of the outcome; hence the sample size
is reduced. The main problem occurs if the intervention
affects different outcomes in different ways. In this trial,
if the use of the decision-support software decreased
deaths but increased significant morbidity there may be
no difference in the short term primary outcome between
the two arms of the trial, even though deaths were being
prevented in one arm. The probability of this situation
occurring appears very small. If decision-support prevents
perinatal asphyxia it will have an effect on all the
outcomes contained within the combined primary
outcome.
Long term
PARCA-R composite score [28, 29] at the age of 2 years
for all infants with trial primary outcome and a further
subset of 7000 babies.
Note: Neurodevelopmental delay and cerebral palsy are
the most important long-term adverse outcomes associated
with perinatal asphyxia. However the incidence of moderate
or severe cerebral palsy is of the order of 1.5–2.5/1000 live
births, depending on the definition and the method of
ascertainment. There is also uncertainty about the proportion
of these cases that results from intrapartum asphyxia in
mature infants; however, 30 % is a reasonable estimate3.
Therefore, given the rarity of this outcome, it is unlikely
that a clear difference could be demonstrated between the
two groups with a trial of 46,000 births. So in order to have
reassurance that any benefits of the intervention, with
respect to short term outcomes, have not occurred at the
expense of later neurodevelopmental delay,we will measure
neurodevelopment in a proportion of the surviving children
at the age of 2 years.
Secondary outcomes
 Intrapartum stillbirth except deaths due to
congenital anomalies
 Neonatal deaths up to 28 days after birth except
deaths due to congenital anomalies
 Moderate or severe encephalopathy
 Admission to neonatal unit within 48 h of birth
for ≥ 48 h with evidence of feeding difficulties,
respiratory illness or encephalopathy (where there is
evidence of compromise at birth)
 Admission to a higher level of care
 Apgar score <4 at 5 min
 The distribution of cord blood gas data for cord
artery pH
 Metabolic acidosis (defined as cord artery pH <7.05
and base deficit in extracellular fluid ≥ 12 mmol/l)
 Resuscitation interventions
 Seizures
 Destination immediately after birth
 Length of hospital stay
Health and development outcomes at 24 months (for
all infants with trial primary outcome and a further subset
of 7000 babies):
Non-verbal Cognition Scale (PARCA-R)
Vocabulary Sub-scale (PARCA-R)
Vocabulary Sub-scale (PARCA-R)
Sentence Complexity Sub-scale (PARCA-R)
Late deaths up to 24 months (after the neonatal period)
Major disability and non-major disability at 2 years
Cerebral palsy
Breast feeding (collected at 12 and 24 months)
Maternal
 Mode of delivery
 Operative intervention (caesarean section and
instrumental delivery) for (i) fetal indication, or (ii)
failure to progress, or (iii) combination of fetal
distress and failure to progress, or (iv) other reason.
 Grade of Caesarean section
 Episiotomy
 Any episode of fetal blood sampling
 Length of (i) first stage, (ii) second stage and (iii)
total length of labour from trial entry
 Destination immediately after birth
 Admission to a higher level of care
Quality of care
All babies with an adverse outcome (trial primary out-
come plus cord-artery pH <7.05 with base deficit ≥
12 mmol/l) and all neonatal deaths and intrapartum
stillbirths will have their care in labour assessed to see if
it was suboptimal. All cases of adverse neonatal outcome
(primary outcome plus cord-artery pH <7.05 with base
deficit ≥ 12 mmol/l) will undergo panel review similar to
that undertaken by CEMACH [16]. Intrapartum notes
will be copied and anonymised, and all references to trial
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allocation will remain. These notes will then be exam-
ined by a panel of experienced obstetricians, midwives
and neonatologists to identify if there was suboptimal
care, particularly in relation to interpretation of the
CTG and actions which flow from any identification of
CTG abnormalities. The panels will also seek to identify
cases with clear evidence of suboptimal care, where the
care could be considered negligent in the event of litiga-
tion. This information will be important for evaluating
whether the decision-support software decreases the risk
of suboptimal care in labour; it will also be useful in the
economic modelling, which will seek to explore the ef-
fect that such an intervention may have on litigation in
obstetrics.
Process outcomes
It is important to collect and analyse process outcomes
in this trial, as a failure to detect differences in clinical
or quality of care outcomes between the two randomised
groups may be due to poor compliance with the alerts of
the system, rather than that the system did not correctly
identify abnormalities with the CTG. In addition, as the
trial allocation is not masked, it will be important to
measure any change that results from clinicians being
aware of whether the decision-support system is in oper-
ation or not. The following outcomes will therefore be
measured to assess this:
 Proportion of women with a CTG abnormality (as
identified by the study software)
 Number of CTG abnormalities identified in the two
arms (as identified by the study software)
 Time taken between alerts and delivery. This can be
achieved in the ‘no decision-support’ arm by using
the decision-support software to analyse the CTG
trace after the trial is over and using this to
determine when the alert would have occurred.
 Number of routine measurements recorded during
labour, including the number of vaginal
examinations, use of epidural analgesia, use of
labour augmentation and presence of meconium.
 Number of thumb entries per hour from time of
trial entry to first yellow level of concern or until
fully dilated
These are proxy measures to assess presence of a
health professional in the delivery room during the
labour which will allow us to quantify any important
differences between the groups with respect to support
offered to women during labour. Although unlikely,
knowledge of the trial allocation may result in less
frequent contact with the woman allocated
‘decision-support’ in labour. Less frequent contact
will result in a lower number of these process
measures.
Data collection
For all participating women and babies, labour variables
and outcomes will be stored automatically and contempor-
aneously onto the Guardian® system. Data collected via the
system will be sent electronically to the trial co-ordinating
centre at the UCL Clincial Trials Unit (UCL CTU) in
London. Data will be extracted from the notes of babies
admitted to the neonatal unit and for all neonatal deaths. It
should be noted that not all data fields are collected at
every centre. However, where an item is collected these
data will be sent to the UCL CTU. The trial is not collect-
ing the reason why continuous EFM is being used, as this
is not recorded. All children surviving to be discharged
home from hospital following their birth will be ‘flagged’ at
the NHS Information Centre for those born in England
and Scotland and all deaths occurring after discharge home
from hospital will be notified to the trial co-ordinating
centre at the UCL CTU. At 2 years after trial entry a sam-
ple of 7000 surviving children (3500 in each group) will be
followed up at 2 years of age. This sample will be taken
from within the sample recruited during the first 2 years of
the project so that follow-up of this group can be com-
pleted around the time that the trial stops recruiting. As
there seems little possibility that the nature of the effect of
the intervention will vary over the duration of trial recruit-
ment, this process will be the most efficient use of re-
sources. For children in the follow-up group, their family
will be sent a two part parent-completed questionnaire to
assess the child’s health, development and well-being. The
first part of the questionnaire comprises the PARCA-R,
which has been previously validated as a means of asses-
sing neurodevelopment in a trial setting. The second part
focuses on general health issues, and has also been used
previously [28, 29]. Major disability at 2 years will be
assessed by questionnaires sent to the child’s parents and
health care professionals. Major disability will be defined
according to the criteria set out in the National Perinatal
Epidemiology Unit (NPEU) and Oxford Regional Health
Authority document and will include any major disability
in the following domains: neuromotor function, seizures,
auditory function, communication, visual function, cogni-
tive function and other physical disability [30, 31].
Health economics
A prospective economic evaluation will be conducted
alongside the trial, with the aim of estimating the cost-
effectiveness of the intelligent decision-support software.
The economic evaluation will be conducted from a
health-service perspective. Information on resource util-
isation will be collected through the Guardian® system
and hospital-patient administration and maternity infor-
mation systems. Observational research methods may be
used to collect additional costs in intrapartum, postpar-
tum or neonatal care. Current UK unit costs will be
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applied to each resource item to value total resource use
in each arm of the trial. A per diem cost for each level
of intrapartum, postnatal and neonatal care will be cal-
culated using NHS reference costs where appropriate, or
by sending a detailed questionnaire to the finance de-
partment of each centre participating in the trial. The
unit costs of clinical events that are unique to this trial
will be derived from the hospital accounts of the centres
participating in the trial, although primary research may
also be required. An incremental cost-effectiveness ana-
lysis will be performed and primarily expressed in terms
of an incremental cost per poor-perinatal-outcome pre-
vented. The primary outcomes of the trial are likely to
have longer-term consequences in terms of health status
and health-service utilisation over the mother’s and in-
fant’s lifetime. Consequently, two long term economic
evaluations are planned, which in the first instance will
estimate the cost-effectiveness of the decision-support
software when surviving children reach 2 years of age,
and in the second instance will incorporate the lifetime
cost and health consequences of the mother and child.
To inform the long-term economic evaluations, a sub-
sample of 700 healthy infants selected within the first
year of recruitment and all babies with the primary trial
outcome who survive to hospital discharge and agree to
follow-up will be followed up until 2 years of age or until
the end of the trial, whichever comes first. Economic
questionnaires completed when the infant reaches 1 and
2 years of age will document the health and social care
use of the child and mother. Cost data collected until
hospital discharge and from the parental questionnaires
will be combined with the PARCA-R composite score at
2 years of age to inform the incremental cost per disabil-
ity free life years gained when surviving children reach 2
years of age [32]. Given the potential long-term sequelae,
these data will then be used to extrapolate long-term out-
comes and costs over the child’s lifetime, identifying future
health care costs and the health status of mothers and in-
fants from literature as well as the application of decision-
analytic or markov methods to synthesise information from
different sources. This will require modeling longer-term
health-service utilisation from literature and also estimating
the potential medico-legal claims that result from adverse
events during the intrapartum and neonatal periods.
Proposed sample size
The proposed sample size is 46,000 births in total.
The following data sources and assumptions have been
used in the calculation of the trial sample size:
Incidence of intrapartum stillbirth
This has been estimated as 0.35 per 1000 births. This esti-
mate is derived from the following incidence data: 0.51
per 1000 for all gestations (England, Wales and Northern
Ireland, 2004) [33]; 0.27 per 1000 for gestation ≥ 37 weeks
(Trent Region, 2002) [34]. This trial is restricting eligibility
to women over 35 weeks’ gestation; therefore the inci-
dence will be lower than in women of all gestational ages,
which includes those with preterm births. However, it will
be higher than for women at term. As women being re-
cruited are all judged to require continuous electronic
fetal monitoring it can be assumed that the identification
of this “risk group” means that these women are at in-
creased risk of adverse outcomes; therefore the incidence
may be higher. In addition these estimates use a denomin-
ator of all births which includes women having elective cae-
sarean sections who are not at risk of intrapartum stillbirth
as they have no “intrapartum” period. Approximately 7 % of
women have elective caesarean section and removal of these
women will increase the incidence further. An estimate of
0.35 per 1000 births, therefore, appears reasonable.
Incidence of neonatal death
This has been estimated as 0.7 per 1000 births. This esti-
mate is derived from the following data: 3.4 per 1000 for
all gestations (England, Wales and Northern Ireland,
2004) [33]; 0.89 per 1000 in those with gestation ≥
37 weeks (Trent Region, 2005) [32]. This trial is restrict-
ing eligibility to women 35 weeks’ gestation or over;
therefore the incidence will be lower than amongst
women of all gestational ages, which includes those with
preterm births. However, it will be higher than for
women at term. A reasonable estimate of neonatal death
for babies 35 weeks’ gestation or over is therefore 1.0 per
1000 births. Using data from the Trent Survey 2005,
30 % of neonatal deaths were due to congenital anomal-
ies. Therefore this rate can be reduced to 0.7 per 1000
births. As women being recruited are all judged to re-
quire continuous electronic fetal monitoring it can be
assumed that the identification of this “risk group”
means that these women are at increased risk of adverse
outcomes; therefore the incidence may be higher. An esti-
mate of 0.7 per 1000 births, therefore, appears reasonable.
Incidence of severe and moderate neonatal encephalopathy
The best estimate of the incidence of neonatal encephal-
opathy in babies born 35 weeks’ gestation or over is 1.3
per 1000 (Trent & Northern Region 2002) [35]. How-
ever, as above, women being recruited to this trial are all
judged to require continuous electronic fetal monitoring
which means that they are at increased risk of adverse
outcomes; therefore the incidence may be higher.
Combined outcomes
Data are available on some combined outcomes. For ex-
ample, the incidence of intrapartum stillbirth plus deaths
on labour ward assumed to be due to intrapartum as-
phyxia (the incidence of which is much lower than
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neonatal mortality) plus severe and moderate neonatal en-
cephalopathy was 1.7 per 1000 (95 % CI: 1.5 to 1.9), range
0.8–2.3 (18 hospitals, Trent 2003–4) and 1.9 per 1000
(95 % CI: 1.6 to 2.3), range 0.6–2.3 (12 hospitals, Yorkshire
Neonatal Network 2004–5) [35]. This was for babies born
at 35 weeks’ gestation or above with the incidence of these
outcomes being higher in the larger hospitals, which at-
tract women with more complicated pregnancies.
Incidence of primary outcome for INFANT
We have assumed an incidence of the primary outcome of
3 per 1000 births. This has been calculated by summing the
rate of intrapartum stillbirth, neonatal death and moderate
and severe encephalopathy which gives an incidence of 2.35
per 1000 births. However, added to this figure is mild en-
cephalopathy, which is reported to occur in 1.25 per 1000
births, and other significant morbidity (other admissions to
the neonatal unit within 48 h of birth for ≥ 48 h e.g. feeding
difficulties, respiratory symptoms, seizures), for which there
are no good estimates of incidence. This estimate of 3 per
1000 births errs on the side of caution and an increased in-
cidence of this outcome in the trial will either (a) increase
the power of the trial to demonstrate the same effect size,
or (b) allow detection of a smaller effect size with the same
trial size, or (c) necessitate a smaller trial if the postulated
effect size (or larger) is detected.
Review of primary outcome
During the early part of the trial, and with advice from
the DMC, the primary outcome definition was refined to
ensure it captured babies who were likely to have experi-
enced hypoxia during labour. The component of the pri-
mary outcome “Admission to neonatal unit within 48 h
of birth for ≥ 48 h with evidence of feeding difficulties,
respiratory illness or encephalopathy (where there is
evidence of compromise at birth)” was initially capturing
a range of conditions, many of which were unlikely to be
related to hypoxia. As a consequence, a process of
reviewing each case which fulfilled this component of
the primary outcome was implemented. Neonatal unit
discharge summaries are collected for all babies admit-
ted to the neonatal unit within 48 h of birth for more
than 48 h. For the purposes of data monitoring during
the trial, two members of the co-investigator group
reviewed all cases which fulfilled this criteria and using a
defined data extraction form, ascribed each case as
meeting the primary outcome or not. The data extrac-
tion form included key elements of the neonatal course
which are most likely to be related to intrapartum hyp-
oxia. The form is not an established or validated list of
criteria and the numeric scoring was devised to give
some quantification of the severity of elements of the
clinical course. A score of 3 or greater was agreed to be
evidence that the condition of the baby was likely to be
associated with intrapartum hypoxia, acknowledging that
there remained uncertainty about this, as there is no abso-
lute measure of intrapartum hypoxia. For the final ana-
lysis, all cases meeting the broad primary outcome criteria
will be reviewed by an independent panel of neonatolo-
gists to repeat this process of ascribing each case (masked
to allocation) as fulfilling the definition fo the primary out-
come or not. Each case will be reviewed (independently)
by at least 2 neonatologists and disagreements will be re-
solved by discussion by the group of five neonatologists.
Effect size
The effect size which can be detected with 46,000
women (23,000 in each group), assuming a 5 % level of
significance and 90 % power, is a 50 % reduction in poor
neonatal outcome rate from 3 to 1.5 per 1000. We have
approximated the number of women recruited with the
number of infants born, even though women with a twin
pregnancy are eligible to join the trial. Approximately 1
in 80 pregnancies are twin pregnancies, however, a pro-
portion of these births will occur before 35 weeks’ gesta-
tion and a large proportion of the term births will be by
elective caesarean section. We therefore estimate that
fewer than 1 % of all births in the study will be twins. In
a study of 164 preterm infants [29], the mean (SD)
PARCA-R composite score at 2 years was 80 (SD 33)
and the mean Mental Development Index (Bayley Scales
of Infant Development II) was approximately half a
standard deviation below the standardised mean of 100.
If we assume that a normal group of term infants would
have a PARCA-R composite score half a standard devi-
ation above this sample of preterm infants, then we can
estimate a mean (SD) 2 year score of 96 (SD33). Based
on this estimate, a follow up sample of size 7000 (3500
per arm) in the INFANT study would have over 90 %
power to detect a difference of 3 points in the PARCA-R
component score with a two-sided 5 % significance level.
The incidence of severe metabolic acidosis (cord-artery
pH <7.05) is 10 per 1000 [36–39]. Our proposed sample
size will therefore enable us to detect a 28 % relative risk
reduction in incidence with over 80 % power in those
babies who have their cord artery pH measured.
Assumptions
Variations in some of the assumptions of incidence will
produce marked variations in the required sample size
as the overall incidence is so low. For example, Table 2
illustrates the impact on the required sample size assum-
ing a 5 % level of significance and 90 % power for the
same effect size (a 50 % relative risk reduction).
Primary analysis
The primary analysis will be a comparison of women
and babies allocated to “CTG with no decision support”
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with “CTG with decision support”. Participants will be
analysed in the groups into which they were randomly
allocated, regardless of allocation received. All women
and babies with available data will be included, except
for protocol violations and women randomised in error
who did not give consent or who were under 16 years of
age. The number (percentage) of babies with the com-
posite primary outcome will be presented for each
group, and the risk ratio plus 95 % confidence interval
(CI) will be calculated. Risk ratios will be estimated
using generalised estimating equations (GEE), or a simi-
lar method, adjusting for the stratification factors used
in the randomisation (centre and singleton/twin pregnancy).
This method of analysis will account for the correlation in
outcomes between twins and siblings delivered in a subse-
quent pregnancy during the trial period. A log binomial
model will be used in the first instance, but if convergence is
not achieved then a log Poisson model will be used with a
robust variance estimator [40]. The mean (SD) PARCA-R
Composite score will be presented for each group, and the
mean difference between groups plus 95 % CI will be calcu-
lated and compared using GEE (Gaussian model with
identity link). For secondary outcomes including the compo-
nents of the primary outcome, a 1 % level of statistical sig-
nificance will be employed. Both adjusted and unadjusted
estimates will be presented for all outcomes, but the primary
inference will be based on the adjusted analysis.
Pre-specified subgroup analysis
To examine whether the effect of decision-support is
consistent across specific subgroups of babies, the fol-
lowing subgroup analyses will be undertaken, using the
statistical test of interaction:
 Singletons versus twins
 Suspected IUGR at labour onset versus no growth
restriction
 BMI group for the subset of women with this
recorded: underweight (<18.5); normal (18.5–24.9);
overweight (25–29.9); obese (>30); unrecorded
 Centre
Economic evaluation
All analyses will be conducted on the basis of intention-
to-treat. As the data for costs are likely to be skewed, we
shall use non-parametric bootstrap estimation to derive
95 % confidence intervals for mean cost-differences be-
tween the trial groups [41]. Non-parametric bootstrap
methods will also be used to calculate 95 % confidence
intervals for incremental cost-effectiveness ratios. In the
absence of stochastic data for all variables, a series of
multi-way sensitivity analyses will be undertaken, to ex-
plore the implications of uncertainty on the base-case
incremental cost-effectiveness ratios. In addition, cost-
effectiveness acceptability curves will be constructed
using the net-benefits approach [42].
Loss to follow-up
Loss to follow-up for the short term primary outcome will
be negligible, as most of this information is collected before
the woman leaves the delivery room where she has been re-
cruited. For neonatal outcomes of the small number of ba-
bies admitted to the neonatal unit, we will collect data for
all of these babies through the research midwives employed
by the study in the participating centres. For the rare in-
stances where babies are transferred out of the recruiting
hospital to another hospital for specialist care, data will be
collected from all the hospitals providing care for that child
prior to discharge home or death. At the time of entry to
the study all women will be asked for permission for their
contact details to be downloaded to the trial co-ordinating
centre along with their clinical details from the Guardian®
system. Families selected for follow-up at 2 years will be
contacted by post 8 weeks after birth and informed that
they have been selected for the follow-up study. Contact
with families who agree to take part will be maintained dur-
ing the period between birth and the follow-up assessment
by sending a birthday card each year along with a FREE-
POST change-of-address card to facilitate communication
with UCL CTU about updated contact details.
Trial management
Project timetable and milestones
The aim is to randomise 46,000 women to the trial over
36 months. Approximately 320 women per week will
therefore need to be recruited. A conservative estimate of
the proportion of women who receive EFM in labour and
are therefore eligible for trial entry is 60 %.
Table 2 Sample size assuming 5 % level of significance, 90 % power, 50 % relative risk reduction
Incidence of primary outcome in
‘no decision-support’ group
Incidence of primary outcome in
‘decision-support’ group
Relative risk Total sample size required
3 per 1000 1.5 per 1000 0.5 46,000
4 per 1000 2 per 1000 0.5 34,000
5 per 1000 2.5 per 1000 0.5 27,000
6 per 1000 3 per 1000 0.5 22,000
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Arrangements for research ethics committee approval
The Investigators will ensure that this study is conducted
in accordance with the principles of the current revision
of the Declaration of Helsinki (last amended October
2008) and with relevant regulations and with the MRC
GCP guidelines which are based on ICH Guidelines for
GCP (CPMP/ICH/135/95) July 1996. The trial has
National Research Ethics Service – Northern and York-
shire Research Ethics Committee approval—and local ap-
provals from all the participating centres.
Research governance
The sponsor of the trial is UCL. The trial will be run on a
day-to-day basis by the UCL CTU Project Management
Group. This group reports to the Trial Steering Commit-
tee which is responsible to the Research Sponsor (UCL).
At each participating centre, local Principal Investigators
will report to the Project Management Group via the pro-
ject funded staff based at the UCL CTU.
Insurance
NHS indemnity operates in respect of the clinical treat-
ment being provided. In addition, UCL has appropriate
insurance-related arrangements in place in respect of
the University’s role as Research Sponsor of this study.
Trial steering committee
The trial will be supervised by an independent Trial
Steering Committee (TSC). The precise terms of refer-
ence for the TSC were agreed at their first meeting. A
TSC Charter similar to that used by the DMC (see
below) has been completed.
Data monitoring committee
An independent Data Monitoring Committee (DMC)
has been established for the trial. This is independent of
the trial organisers and will meet yearly. The terms of
reference for the DMC were agreed at their first meet-
ing. A DMC charter has been completed following the
recommendations of the DAMOCLES Study [43].
During the period of recruitment to the trial, interim
analyses will be supplied, in strict confidence, to the DMC,
together with any other analyses the DMC may request.
The data will be supplied to the Chair of the DMC as fre-
quently as they request. Meetings of the committee will be
arranged periodically, as considered appropriate by the
Chair. In the light of interim data, and other evidence from
relevant studies (including updated overviews of the rele-
vant randomised controlled trials), the DMC will inform
the TSC, if in their view there is proof beyond reasonable
doubt that the data indicate that any part of the protocol
under investigation is either clearly indicated or contra-
indicated, either for all women or for a particular subgroup
of trial participants. A decision to inform the TSC will in
part be based on statistical considerations. Appropriate cri-
teria for proof beyond reasonable doubt cannot be speci-
fied precisely. A difference of at least 3 standard errors in
the interim analysis of a major endpoint may be needed to
justify halting, or modifying, such a study prematurely. If
this criterion were to be adopted by the DMC, it would
have the practical advantage that the exact number of in-
terim analyses would be of little importance, and so no
fixed schedule is proposed [44]. Unless modification or
cessation of the protocol is recommended by the DMC,
the TSC, collaborators and administrative staff (except
those who supply the confidential information) will remain
blind to the results of the interim analysis. Collaborators
and all others associated with the study may write through
the trial office to the DMC, to draw attention to any con-
cern they may have about the possibility of harm arising
from the treatment under study, or about any other mat-
ters that may be relevant.
Publication policy
The Chief Investigator will co-ordinate dissemination of
data from this study. All publications using data from
this study to undertake original analyses will be submit-
ted to the TSC for review before release. To safeguard
the scientific integrity of the trial, data from this study
will not be presented in public before the main results
are published without the prior consent of the TSC. The
success of the trial depends on a large number of mid-
wives and obstetricians. For this reason, chief credit for
the results will not be given to the committees or central
organisers, but to all who have collaborated and partici-
pated in the study. Acknowledgement will include all
local co-ordinators and collaborators, members of the
trial committees, the Trial Co-ordinating Centre and
trial staff. Authorship at the head of the primary results
paper will take the form “The INFANT Collaborative
Group”. This avoids giving undue prominence to any
individual. All contributors to the study will be listed
at the end of the report, with their contribution to
the study identified. Those responsible for other pub-
lications reporting specific aspects of the study may
wish to utilise a different authorship model, such as
“[name], [name] and [name] on behalf of the IN-
FANT Collaborative Group”. Decisions about author-
ship of additional papers will be discussed and agreed
by the trial investigators and the TSC. The women
participating in the trial will be sent a summary of
the final results of the study, which will contain a ref-
erence to the full paper. A copy of the journal article
will be available on request.
Time period for retention of relevant trial documentation
The policy of UCL CTU is to retain documentation
from all its research indefinitely as it is always ‘fit for
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purpose’. Clinical research in the perinatal period, par-
ticularly in relation to new interventions, has the poten-
tial to lead to a wide range of unanticipated effects.
Thalidomide and diethylstilboestrol are classic examples.
Although such effects are most likely with new medi-
cines, we cannot be certain that there will be no long-
term consequences of this new technology and that it
may become necessary, in the public interest, to under-
take long-term follow-up of this cohort of recruited
women and children in the future. Any further follow-
up will require the necessary approvals before it can go
ahead.
Discussion
This large randomised controlled trial will evaluate
whether this intelligent system to support decision mak-
ing in the management of labour using the cardiotoco-
graph improves perinatal outcome for babies and
mothers. By accurately identifying abnormal fetal heart
rate patterns associated with perinatal compromise, the
system has the potential to refine the use of intrapartum
interventions such as emergency caesarean section and
instrumental delivery for presumed fetal distress. By cor-
rectly identifing the distressed fetus, intervention can be
offered in a timely way to improve outcomes, but it may
also provide reassurance that the fetus is not compro-
mised and the technology therefore has the potential to
decrease unnecessary intervention.
The results of this trial will have importance for preg-
nant women and for their health professionals.
All changes to this protocol are listed in Table 3.
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